You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2025

Profile for Argentina Patent: 048032


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Argentina Patent: 048032

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
10,106,503 Mar 10, 2025 Mylan Ireland Ltd YUPELRI revefenacin
10,343,995 Mar 10, 2025 Mylan Ireland Ltd YUPELRI revefenacin
11,247,969 Mar 10, 2025 Mylan Ireland Ltd YUPELRI revefenacin
7,288,657 Oct 31, 2028 Mylan Ireland Ltd YUPELRI revefenacin
7,491,736 Mar 10, 2025 Mylan Ireland Ltd YUPELRI revefenacin
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Detailed Analysis of Patent AR048032: Scope, Claims, and Patent Landscape in Argentina

Last updated: July 29, 2025


Introduction

Patent AR048032 pertains to a pharmaceutical invention filed and granted in Argentina. Understanding its scope, specific claims, and the broader patent landscape is critical for stakeholders such as generic manufacturers, patent attorneys, and pharmaceutical companies. This analysis explores AR048032's claims, delineates its inventive scope, and contextualizes its position within Argentina's patent environment and global patent trends.


Overview of Patent AR048032

Patent AR048032 was granted to a pharmaceutical composition or compound patent, likely related to a therapeutic agent or process, consistent with Argentine patent classifications (INPI). While the exact filing date and granted date are not specified in this document, such patents typically date back several years, reflecting prior art considerations and technological evolution.

This patent protects specific chemical entities, pharmaceutical formulations, or methods of use, depending on the claims filed. It aims to secure exclusive rights to prevent unauthorized manufacturing, use, and commercialization within Argentina.


Scope and Structure of Claims

Claims Analysis

The core of any patent's legal scope lies in its claims. Patent AR048032's claims likely encompass a combination of independent claims defining the broadest scope, followed by narrower dependent claims elaborating specific embodiments.

  • Independent Claims:
    These typically define the core invention with language focusing on the chemical structure, formulation, or process. For example, an independent claim might specify a novel chemical compound with specific functional groups or a unique method of synthesis.

    Sample hypothetical claim:
    "A pharmaceutical composition comprising Compound X, characterized by its chemical structure as depicted in Figure 1, for use in treating Disease Y."

  • Dependent Claims:
    These specify particular embodiments, such as specific dosage forms, manufacturing methods, or combination therapies that build on the independent claims.

The claims' language is precise, often involving Markush structures, chemical formulas, or process steps. The scope is designed to encompass all major variations of the core invention while maintaining novelty and inventive step over prior art.

Claims Scope in Argentina

Argentina's patent law (Law 24,481 and subsequent amendments) emphasizes novelty, inventive step, and industrial application. Patent claims are scrutinized for clarity and scope—meaning overly broad claims risk rejection or invalidation. The patent's scope, therefore, reflects a balance: broad enough to prevent competitive copying but specific enough to withstand legal and patentability standards.


Patent Landscape in Argentina

National Patent System and Policy

Argentina's patent system aligns with older and regional standards, with notable recent updates via the INPI (Instituto Nacional de la Propiedad Industrial) to modernize procedures. Pharmacological inventions often face challenges concerning prior art—both local and international.

Pharmaceutical Patent Trends

The patent landscape for pharmaceuticals in Argentina has historically shown cautious acceptance of patentability for chemical entities. However, recent reforms and adherence to TRIPS obligations have bolstered patent protections, particularly for innovative compounds and formulations.

Major Patent Families and Competitors

AR048032 exists within a landscape featuring:

  • Patents covering similar chemical classes from patent families originating in the US, Europe, and Japan.
  • Local filings that could challenge or complement AR048032, especially if overlapping therapeutic claims exist.
  • Generic pressures stemming from local manufacturing companies that might seek to design-around or challenge patent validity.

Litigation and Patent Term Considerations

While Argentina's patent enforcement mechanisms are evolving, patent validity is often confirmed via nullity proceedings, especially if generic competitors contest the patent on grounds of novelty or inventive step.


Legal Status and Vulnerabilities

  • The patent’s enforceability hinges upon its maintenance fees and validity over prior art.
  • Potential vulnerabilities include prior disclosure, lack of inventive step, or obviousness considering existing chemical variants.
  • Patent term adjustments are limited in Argentina; patents generally have a 20-year term from filing, with potential extensions for regulatory approval delay.

Implications for Stakeholders

  • Innovators: Patent AR048032 affirms regional exclusivity, enabling market control.
  • Generics: Must analyze patent claims meticulously for potential workarounds or invalidity grounds.
  • Legal Advisors: Need to scrutinize claim scope against prior art to identify vulnerabilities.

Key Takeaways

  • Scope interpretation indicates a focus on specific chemical structures or formulations with potential patent breadth, subject to Argentine patent law standards.
  • Patent landscape reflects regional and international patent filings, with ongoing challenges related to prior art and patent validity.
  • Legal enforceability depends on strict claim adherence, timely maintenance, and overcoming potential patent invalidity challenges.
  • Strategic considerations include monitoring patent expiration dates and navigation of patent challenges to maximize market opportunities.

FAQs

1. What is the typical patent term for pharmaceutical patents in Argentina?
The standard term is 20 years from the filing date, with potential adjustments for regulatory delays, subject to annual fee payments.

2. How broad are the claims generally in pharmaceutical patents like AR048032?
Claims vary but often include broad formulations or compound classes, balanced to withstand prior art challenges while providing adequate protection.

3. Can AR048032 be challenged or invalidated in Argentina?
Yes; validity can be contested through nullity actions based on prior art, lack of novelty, or inventive step. Argentine law allows third parties to initiate such proceedings.

4. What is the impact of regional patent law on pharmaceutical patent protection?
Argentina's patent law emphasizes specific, clear claims and requires pharmaceutical inventions to demonstrate genuine novelty and inventive step, influencing claim drafting and enforcement strategies.

5. How does Argentina’s patent landscape influence global pharmaceutical patent strategies?
It encourages filings that demonstrate genuine inventive contribution, discourages overly broad claims, and demands thorough prior art searches, aligning regional protections with global standards.


References

  1. Argentine Patent Law (Law 24,481)
  2. INPI Argentina patent guidelines and patent publication data
  3. TRIPS Agreement. World Trade Organization.
  4. Recent patent filings and legal cases in Argentina's pharmaceutical sector.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.